UBS Group’s Antares Pharma, Inc. ATRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-5,700
| Closed | -$23K | – | 11684 |
|
|
2022
Q1 | $23K | Sell |
5,700
-17,794
| -76% | -$64.6K | ﹤0.01% | 7325 |
|
|
2021
Q4 | $83K | Buy |
23,494
+719
| +3% | +$2.52K | ﹤0.01% | 6479 |
|
|
2021
Q3 | $83K | Sell |
22,775
-880
| -4% | -$3.56K | ﹤0.01% | 5960 |
|
|
2021
Q2 | $103K | Sell |
23,655
-32,486
| -58% | -$132K | ﹤0.01% | 5859 |
|
|
2021
Q1 | $230K | Sell |
56,141
-69,992
| -55% | -$303K | ﹤0.01% | 5389 |
|
|
2020
Q4 | $503K | Buy |
126,133
+96,519
| +326% | +$312K | ﹤0.01% | 4597 |
|
|
2020
Q3 | $80K | Sell |
29,614
-75,525
| -72% | -$209K | ﹤0.01% | 5315 |
|
|
2020
Q2 | $290K | Sell |
105,139
-30,221
| -22% | -$84.3K | ﹤0.01% | 4539 |
|
|
2020
Q1 | $320K | Sell |
135,360
-72,840
| -35% | -$248K | ﹤0.01% | 4343 |
|
|
2019
Q4 | $979K | Buy |
208,200
+78,376
| +60% | +$321K | ﹤0.01% | 4235 |
|
|
2019
Q3 | $435K | Buy |
129,824
+79,344
| +157% | +$261K | ﹤0.01% | 4684 |
|
|
2019
Q2 | $166K | Buy |
50,480
+9,024
| +22% | +$26.1K | ﹤0.01% | 5038 |
|
|
2019
Q1 | $126K | Sell |
41,456
-38,238
| -48% | -$124K | ﹤0.01% | 4918 |
|
|
2018
Q4 | $217K | Buy |
79,694
+38,699
| +94% | +$127K | ﹤0.01% | 4901 |
|
|
2018
Q3 | $138K | Buy |
40,995
+20,080
| +96% | +$62K | ﹤0.01% | 5329 |
|
|
2018
Q2 | $54K | Buy |
20,915
+18,915
| +946% | +$47.1K | ﹤0.01% | 5916 |
|
|
2018
Q1 | $4K | Sell |
2,000
-12,986
| -87% | -$29.2K | ﹤0.01% | 7364 |
|
|
2017
Q4 | $30K | Buy |
14,986
+2,228
| +17% | +$4.85K | ﹤0.01% | 6244 |
|
|
2017
Q3 | $41K | Buy |
12,758
+4,758
| +59% | +$14.7K | ﹤0.01% | 5941 |
|
|
2017
Q2 | $26K | Buy |
8,000
+1,500
| +23% | +$4.25K | ﹤0.01% | 6119 |
|
|
2017
Q1 | $18K | Sell |
6,500
-8,055
| -55% | -$19.4K | ﹤0.01% | 6227 |
|
|
2016
Q4 | $34K | Buy |
14,555
+12,555
| +628% | +$23.9K | ﹤0.01% | 6146 |
|
|
2016
Q3 | $3K | Sell |
2,000
-15,224
| -88% | -$18.7K | ﹤0.01% | 7327 |
|
|
2016
Q2 | $18K | Buy |
17,224
+15,224
| +761% | +$14.7K | ﹤0.01% | 6394 |
|
|
2016
Q1 | $2K | Sell |
2,000
-9,940
| -83% | -$9.62K | ﹤0.01% | 7348 |
|
|
2015
Q4 | $14K | Sell |
11,940
-8,379
| -41% | -$11.7K | ﹤0.01% | 7092 |
|
|
2015
Q3 | $34K | Buy |
20,319
+14,619
| +256% | +$28.7K | ﹤0.01% | 6186 |
|
|
2015
Q2 | $12K | Sell |
5,700
-5,701
| -50% | -$13.8K | ﹤0.01% | 7336 |
|
|
2015
Q1 | $30K | Sell |
11,401
-11,264
| -50% | -$28.6K | ﹤0.01% | 6555 |
|
|
2014
Q4 | $59K | Buy |
+22,665
| New | +$50.9K | ﹤0.01% | 6283 |
|
Other funds holding ATRS
UBS Group's ATRS Position: Q2 2022 in Review
UBS Group sold out of Antares Pharma, Inc. (ATRS) in Q2 2022, closing a stake of 5,700 shares — an estimated $23K sold.
UBS Group first reported a position in ATRS in Q4 2014 and held it in 30 quarters. The position peaked at $979K in Q4 2019. 1 fund tracked by Wall St. Rank holds ATRS as of Q2 2022.
- UBS Group reported no remaining Antares Pharma, Inc. position as of Q2 2022 after selling out during the quarter.
- UBS Group sold 5,700 Antares Pharma, Inc. shares in Q2 2022, an estimated $23K.
- UBS Group first reported a position in Antares Pharma, Inc. in Q4 2014 and held it in 30 quarters.
- UBS Group's Antares Pharma, Inc. position peaked at $979K in Q4 2019.
- 1 fund tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2022.
Based on UBS Group's 13F filing for Q2 2022, filed 10 Aug 2022.